KURA Aktie
WKN: 676143 / ISIN: JP3268200007
07.08.2025 23:07:39
|
Kura (KURA) Revenue Drops 61%
Kura Oncology (NASDAQ:KURA), a clinical-stage company specializing in precision cancer medicines, released its second quarter 2025 financial results on August 7, 2025. The headline news was a sharp miss on collaboration revenue, with $15.3 million (GAAP) reported versus analyst expectations of $39.1 million. As there are still no product sales, all revenue in the period reflected payments under partnership agreements. Operating expenses in R&D and administration rose significantly from the prior year, widening the net loss to $66.1 million (GAAP). While Kura continued clinical and regulatory momentum with its lead asset ziftomenib, the quarter highlights mounting financial pressure as the company ramps toward potential commercial operations. Source: Analyst estimates for the quarter provided by FactSet. Kura Oncology is focused on developing targeted therapies for genetically defined cancers. The company’s primary asset is ziftomenib, a menin inhibitor drug designed for genetically defined subtypes of leukemia such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Ziftomenib is being evaluated in the relapsed/refractory NPM1-mutant AML population, a group with limited current treatment options.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu KURA CORPmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu KURA CORPmehr Analysen
Aktien in diesem Artikel
KURA CORP | 3 350,00 | 1,21% |
|